Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Med Klin (Munich) ; 97(3): 128-36, 2002 Mar 15.
Article in German | MEDLINE | ID: mdl-11957787

ABSTRACT

OBJECTIVE: To create a concept for measuring and valuating resource utilization of outpatient treatment of patients with inflammatory bowel disease in a German university hospital. MATERIAL AND METHODS: The measurement of health services was achieved using a computer-based routinely administered data base of the Medical Department. Measuring costs was performed in three steps: 1. identification of the categories of resource utilization, 2. quantitative measurement of resource use, 3. monetary valuation of the utilization of resources using German fee schedules and prices for drugs. RESULTS: The resource utilization of 272 patients with a treatment period of more than 1 year could be identified in a structured form. Categories of resource use could be identified and quantitatively measured as follows: anamnesis and physical examination by a physician in 100% of the visits, laboratory tests in 87.1%, endoscopic or sonographic services in 36.9%, and radiologic procedures in 14.1%. In 93.6% of the visits a medication was prescribed. Annual costs of outpatient care provided by the hospital were 3,171 [symbol: see text] per patient. Medication accounted for 85% of total costs. Analyzing the costs of medical treatment, mesalazine was the major cost component (48%), followed by budesonide (15%). CONCLUSION: The presented concept offers a good access to measure costs of outpatient treatment of patients with inflammatory bowel disease. It is suitable for measuring costs in the economic evaluation of alternative treatments or diagnostic strategies in an outpatient setting. It furthermore may be used as a component in cost-of-illness studies. For transferring the concept to other hospitals, the availability of a routine documentation of services should be checked. For economic analysis, a further data management is required.


Subject(s)
Ambulatory Care/economics , Colitis, Ulcerative/economics , Cost of Illness , Crohn Disease/economics , Drug Costs , Health Care Costs , Hospitals, University/economics , Adult , Anti-Inflammatory Agents/economics , Anti-Inflammatory Agents/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/economics , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Budesonide/economics , Budesonide/therapeutic use , Colitis, Ulcerative/drug therapy , Costs and Cost Analysis , Crohn Disease/drug therapy , Germany , Health Resources/economics , Health Resources/statistics & numerical data , Humans , Mesalamine/economics , Mesalamine/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...